You have a credible early-stage clinical concept with unusually good pilot access: an 8-patient prototype test, a geriatrics department head willing to sponsor a formal study, and an existing geriatrician/software team. The biggest strategic mistake would be treating this primarily as an “AI chatbot.” The company should be positioned as a medication-safety and care-management infrastructure product for older adults with polypharmacy, with conversational AI as the interaction layer. I’m assuming the initial commercialization market is the United States, because your goal explicitly includes FDA clarity, health-system contracts, and HIPAA. If you intend to launch first in Malaysia or another country, the regulatory/commercial pathway changes substantially. Executive strategy Recommended positioning > An AI-assisted medication adherence and early-risk detection platform for older adults with complex medication regimens, connecting patients, caregivers, and primary-care teams before nonadherence becomes a clinical event. Your initial buyer should be health systems / primary-care or geriatrics organizations, not individual elderly consumers. The commercial chain should be: Health system → care team → patient + caregiver rather than: Patient → app That gives you a much stronger economic story because the health system can potentially benefit from reduced avoidable utilization, better chronic-disease management, improved medication adherence, and better quality performance. There is also a particularly interesting payer angle: CMS's Part D Star Ratings include medication-adherence measures for diabetes, hypertension/RAS antagonists, and statins, each carrying meaningful weighting. Your most important strategic decision Do not make “preventing emergency-department visits” the first clinical claim. A 50-patient pilot cannot credibly establish that your system prevents ED visits. Instead: Primary pilot hypothesis > The platform is feasible, acceptable, safe, and capable of identifying medication-adherence problems earlier than usual care. Secondary/exploratory outcomes adherence medication-related problems identified intervention/escalation rate caregiver engagement clinician workload patient satisfaction urgent-care/ED utilization as an exploratory endpoint Then a subsequent larger controlled study can test whether the intervention actually changes hospitalization/ED outcomes. --- 1. HEALTH TECH MARKET ANALYSIS 1.1 Market opportunity Don't pitch this as the enormous generic “digital health market.” Your addressable market is much narrower and more attractive: Older adults + polypharmacy + chronic disease + primary-care/care-management workflows. Your economic stakeholders are: Stakeholder Problem Older adult Forgetting, confusion, side effects, regimen complexity Family caregiver Doesn't know whether medications were taken PCP Finds out about adherence problems too late Geriatrician High medication complexity and limited staff time Health system Avoidable utilization and care-management burden Medicare Advantage plan Medication adherence affects quality performance Pharmacy Medication synchronization/adherence opportunities The strongest commercial wedge is therefore: High-risk older adults with 5+ medications receiving primary care. Don't initially target every medication-taking adult. --- 1.2 B2B vs B2C vs B2B2C Recommended: B2B2C The economic buyer is the healthcare organization. The user is the patient. The secondary user is the caregiver. The clinical user is the PCP/care manager. That gives you a four-sided product: Patient → conversational check-in Caregiver → escalation/support Care team → actionable alerts Health system → population dashboard + outcomes This is much more defensible than a consumer medication reminder app. --- 1.3 Buyer vs user distinction This needs to be explicit in the product architecture. Economic buyer Initially: Chief Medical Officer VP Population Health VP Value-Based Care Medical Director Director of Care Management Geriatrics leadership Clinical champion Most likely: geriatrician PCP pharmacist nurse care manager Operational buyer Potentially: population-health director care-management director digital-health director End user older adult caregiver IT/security gatekeeper CIO/CTO CISO privacy officer informatics EHR/integration team Your sales strategy needs to win all five groups, not just the physician. --- 1.4 Competitive landscape Your competitors aren't only AI companies. They fall into five categories: Category A — Medication reminder apps Strength: simple inexpensive Weakness: largely passive don't close the loop with clinicians Category B — Medication adherence platforms Strength: adherence analytics pharmacy integration Weakness: often designed around claims/refill behavior rather than daily patient interaction Category C — Remote patient monitoring / chronic-care platforms Strength: existing health-system relationships Weakness: medication adherence isn't always the central workflow Category D — Digital therapeutics / conversational AI Strength: sophisticated engagement Weakness: often focused on specific diseases rather than polypharmacy Category E — Human care-management programs This is your most important competitor. A hospital may say: > “Our nurses already call these patients.” Your answer needs to be: > “We don't replace your nurses. We make the nurse's scarce intervention time more productive by identifying which patients need attention today.” That is an extremely important positioning shift. --- 1.5 Reimbursement/payment model Don't make reimbursement your first dependency. Instead use a software/service contract. Phase 1 Health system pays: annual platform fee + per enrolled patient/month Example eventual pricing hypothesis: $5–$15 PMPM for lower-touch deployment $15–$30 PMPM for high-risk care-management deployment These are pricing hypotheses to test, not established market prices. Phase 2 Explore: Medicare Advantage partnerships value-based-care contracts ACOs payer-sponsored programs care-management programs Why the payer opportunity is interesting Medication adherence is already embedded in Medicare Part D quality measurement. CMS's 2026 Star Ratings include adherence measures for diabetes medications, RAS antagonists, and statins. That gives you a potential payer ROI narrative: better adherence → better quality performance → potentially better economics But don't claim that your product automatically improves Star Ratings. You'll need evidence. --- 1.6 Market-entry strategy I recommend this sequence: Geriatrics department ↓ High-risk primary-care cohort ↓ 50-patient pilot ↓ Second health-system pilot ↓ 3 health-system contracts ↓ Medicare Advantage / ACO expansion This is much more realistic than launching directly as a national consumer application. --- 2. PRODUCT-MARKET FIT VALIDATION 2.1 Your core PMF hypothesis Your current hypothesis is: > Older adults with complex medication regimens will voluntarily interact with a conversational AI system frequently enough that the system can identify meaningful adherence problems earlier than routine care, while producing alerts clinicians actually consider useful. Break that into six testable hypotheses. H1 — Engagement ≥70% of enrolled patients complete the required daily interaction. H2 — Detection The platform identifies a meaningful percentage of adherence problems before they are identified through routine clinical processes. H3 — Clinical usefulness Clinicians judge ≥70% of escalations to be actionable/useful. H4 — Safety False or inappropriate escalations remain below a predefined threshold. H5 — Workflow Care-team intervention takes less than a predefined amount of staff time per patient/week. H6 — Commercial value The health system believes the measured improvement is economically valuable enough to purchase. --- 2.2 Clinical problem validation Before expanding the prototype, interview: 15–20 older adults Ask: Why do you miss medications? Which medications are hardest? What happens when you miss them? How do you remember? Who knows when you miss? Would you tell an AI assistant? What would make you distrust it? What would make you stop using it? 10–15 caregivers Especially: adult children spouses family members managing medication remotely 10–15 clinicians Including: geriatricians PCPs pharmacists nurses care managers 5–10 health-system executives Ask a completely different question: > “What would have to be true for you to spend $X per patient per month on this?” --- 2.3 Design for elderly users Do not build a generic chatbot. Design around: large text simple conversation predictable prompts minimal navigation voice-first interaction multilingual capability where appropriate repetition tolerance hearing/vision limitations cognitive impairment screening caregiver fallback The AI should not say: > “How are you feeling about your medication adherence today?” It should behave more like: > “Good morning, Mrs. Smith. Let's check your morning medicines. Did you take your blood-pressure medicine?” That is much easier to use. --- 2.4 Critical clinical safety architecture The AI should not independently make medication decisions. For example, it should never tell a patient: > “Your blood pressure medication is making you dizzy, so stop taking it.” Instead: > “I'm sorry you're feeling dizzy. I want to make sure your care team knows. I've sent this information to your care team.” That distinction matters enormously for FDA risk, clinical liability, and trust. --- 2.5 Alert hierarchy Avoid flooding clinicians. Build three levels: Green Routine adherence confirmation. No clinical action. Yellow Potential adherence issue. Aggregated into clinician dashboard. Red Potential urgent safety issue. Examples might include: repeated missed high-risk medication reported severe adverse symptoms inability to obtain medication confusion about dosing repeated nonresponse The red pathway should have explicit human escalation rules. --- 3. REGULATORY AND COMPLIANCE STRATEGY This is the area where I would spend money before building the formal pilot. You currently have no regulatory expertise. That is your largest immediate weakness. 3.1 FDA pathway Your product could potentially sit in a relatively favorable regulatory position if you deliberately constrain its intended use and claims. FDA's January 2026 final Clinical Decision Support guidance distinguishes certain non-device CDS functions from software that remains subject to device regulation. FDA also specifically describes software that prompts patients to adhere to predetermined medication dosing schedules as an example of a function for which it intends to exercise enforcement discretion. That is encouraging. But your product goes beyond a simple reminder. You propose: AI conversation → identify adherence problem → alert clinician Therefore, you need a formal intended-use analysis. --- 3.2 Recommended regulatory architecture Design the first version around: Function 1 Medication reminders. Function 2 Patient-reported adherence collection. Function 3 Structured identification of predefined adherence barriers. Function 4 Routing information to clinicians. Function 5 Human clinician review. Avoid initially: diagnosis medication selection dose changes treatment recommendations autonomous clinical decisions predicting a specific medical event “preventing hospitalization” claims FDA explicitly notes that software functions need to be assessed individually and that the CDS guidance should not be used as the sole regulatory analysis. --- 3.3 FDA regulatory goal Your stated goal is: > “achieve FDA regulatory clarity.” Good. I would not make the goal: > “get FDA approval.” Instead: Months 1–4 Regulatory classification assessment. Months 3–5 FDA Pre-Submission/Q-Sub preparation. Months 5–7 Submit questions to FDA. Months 6–8 Incorporate feedback into pilot and product architecture. FDA's Q-Submission program is specifically designed to facilitate interaction with FDA concerning medical-device submissions and related regulatory questions. That is likely more valuable to you than guessing. --- 3.4 If FDA considers it a device Do not assume 510(k). The eventual pathway could depend heavily on the precise intended use, technological characteristics, risk profile and predicate landscape. Potential possibilities could include: non-device software enforcement discretion 510(k) De Novo The correct strategy is therefore: regulatory classification → FDA feedback → evidence plan → submission strategy not: assume 510(k) → build product around assumption FDA's software-submission guidance describes the documentation expected for device software functions when a premarket submission is required. --- 3.5 HIPAA checklist If your health-system partner is a covered entity and your platform handles PHI on its behalf, structure the company as a healthcare business associate where appropriate. You need: BAA infrastructure access controls authentication authorization audit logging encryption secure backups disaster recovery incident response vulnerability management penetration testing risk analysis risk-management documentation minimum-necessary data handling vendor risk management data-retention policies deletion policies workforce security privacy policies breach-response procedures HHS states that cloud providers processing ePHI generally require a HIPAA-compliant BAA and that covered entities/business associates must conduct risk analyses. The Security Rule also requires ongoing risk management and review of safeguards. --- 3.6 Family-member access This needs to be designed carefully. Don't simply give family members everything. Build patient-controlled permissions: Patient → chooses caregiver → chooses what caregiver can see → chooses notification categories → can revoke access HHS permits certain disclosures to people involved in a patient's care under specified circumstances, but you should not use that as a substitute for a deliberately designed consent/authorization model. --- 3.7 IRB and pilot ethics Before the 50-patient pilot: 1. Define intended use. 2. Determine whether this is research. 3. Develop protocol. 4. Define risks. 5. Define inclusion/exclusion criteria. 6. Develop informed-consent process. 7. Establish data-management plan. 8. Establish adverse-event/escalation process. 9. Obtain IRB approval. 10. Determine device risk classification if applicable. If FDA considers the software a device, the study's risk status matters. FDA distinguishes significant-risk and nonsignificant-risk investigations; NSR studies generally require IRB approval without an FDA IDE submission, whereas significant-risk studies require FDA IDE approval plus IRB approval before starting. Do not let the geriatrics department simply “start the pilot.” Have regulatory counsel and the IRB determine the correct pathway first. --- 3.8 State licensing The software company generally shouldn't be structured as though it is independently practicing medicine. Your product should: detect → organize → notify → support rather than: diagnose → prescribe → treat Also review: telehealth laws nurse/physician scope-of-practice corporate-practice-of-medicine rules state privacy laws consent requirements automated communication rules breach notification requirements This becomes more important if your company begins providing clinical services rather than software. --- 4. CLINICAL EVIDENCE STRATEGY 4.1 The 50-patient study Don't call it a definitive efficacy trial. Call it something like: > Prospective pilot study evaluating feasibility, usability, safety and preliminary medication-adherence outcomes of an AI-assisted medication adherence platform in older adults with polypharmacy. That's much more defensible. --- 4.2 Suggested study structure Population Older adults: approximately ≥65 multiple chronic conditions ≥5 medications/day receiving care at participating clinic documented adherence risk Potential exclusion: inability to provide consent severe cognitive impairment without appropriate caregiver structure inability to interact with the technology unstable clinical condition situations where delayed escalation would create unacceptable risk The exact criteria should be determined with your clinical investigator/IRB. --- 4.3 Study duration I'd target: 12 weeks per patient rather than only 30 days. This gives you enough interaction data to examine: sustained engagement adherence trends alert frequency dropout caregiver involvement clinician workload --- 4.4 Primary endpoints For this first study, I'd prioritize: Feasibility Percentage successfully enrolled and retained. Engagement Percentage of expected check-ins completed. Usability Validated usability/acceptability questionnaire. Safety Number and severity of: missed escalations inappropriate escalations false alarms technical failures adverse events associated with system use --- 4.5 Secondary endpoints Measure: medication adherence number of adherence problems detected time from problem onset to detection clinician intervention rate caregiver notification rate patient confidence caregiver burden clinician workload --- 4.6 Exploratory outcomes This is where you can collect: ED visits hospitalizations urgent care medication-related events PCP contacts But label them exploratory. With only 50 participants, you won't have enough statistical power to confidently demonstrate ED-visit reduction unless the effect is extraordinarily large. --- 4.7 Establish a ground truth This is critical. Your AI says: > “Patient appears nonadherent.” How do you know? Create a reference standard using multiple sources: patient report caregiver report medication reconciliation pharmacy/refill information where available clinician assessment structured adherence questionnaire Then calculate: sensitivity specificity positive predictive value false-positive rate false-negative rate This will make your clinical paper dramatically stronger. --- 4.8 Clinical evidence ladder Your evidence program should eventually become: 8-patient informal prototype ↓ 50-patient prospective feasibility pilot ↓ 100–300 patient controlled study ↓ multi-site prospective study ↓ health-economic analysis ↓ large-scale real-world evidence That is the evidence ladder investors and health systems will understand. --- 5. CLINICAL PARTNERSHIP STRATEGY Your geriatrics department head is currently your most valuable asset. Turn that individual into a formal: Clinical Founding Advisor / Principal Investigator Get agreement on: pilot protocol recruitment clinical escalation medication-risk definitions endpoint selection publication conference presentation subsequent multi-site research Then recruit: 2 additional health systems Not immediately for commercial contracts. First as: external validation sites. That gives you multi-site evidence. --- 6. PUBLICATION STRATEGY Build publication into the study from day one. Potential paper sequence: Paper 1 Feasibility and acceptability of conversational AI for medication adherence among older adults with polypharmacy Paper 2 Performance of AI-assisted identification of medication-adherence barriers Paper 3 Clinical and economic impact of AI-supported medication adherence intervention The first publication should avoid exaggerated claims. The scientific credibility becomes part of your sales strategy. A peer-reviewed publication can substantially reduce perceived risk for hospital buyers. --- 7. HEALTH TECHNOLOGY ASSESSMENT Eventually demonstrate: Clinical value Does adherence improve? Operational value Does the care team spend less time finding problems? Economic value Does the health system reduce: avoidable utilization care-management workload medication-related complications? Patient value Does the patient feel: more confident more independent less overwhelmed? Your ultimate economic model should be: > Cost of platform < value of clinical improvement generated --- 8. COMMERCIALIZATION STRATEGY 8.1 Your first commercial customer Don't sell to a huge national health system first. Target: mid-sized integrated health systems with strong geriatrics/population-health programs. Ideal characteristics: 50,000–500,000+ patients Medicare population value-based contracts established care-management team Epic or similar EHR strong geriatrics department interest in digital health executive champion --- 8.2 First sales pitch Don't say: > “Our AI chatbot reminds seniors to take their medicine.” Say: > “We identify medication-adherence problems before they become clinical problems and route the right patients to your care team.” That is a much more valuable proposition. --- 8.3 EHR integration Initially, don't attempt an enormous integration project. MVP Secure dashboard + clinician alerts. Version 2 FHIR/SMART-on-FHIR integration. Version 3 Deep EHR integration: medication list care-team notifications documentation patient context clinical workflow The product should fit existing workflow rather than create another inbox. --- 8.4 Alert workflow The worst possible product is: > “AI generated 37 alerts today.” The ideal product is: > “8 patients need attention today.” And each alert should answer: 1. What happened? 2. Why does it matter? 3. What medication? 4. How long? 5. What did the patient say? 6. What should the clinician do? 7. Has anyone already contacted the patient? --- 8.5 Health-system procurement timeline Plan for approximately: 0–2 months Clinical champion + business case 2–4 months Security/privacy review 3–6 months Pilot contract 4–7 months IT integration 6–9 months Implementation 9–12 months Outcome review 12–18 months Enterprise expansion This is why you should begin selling during the pilot, not after publication. --- 8.6 Champion strategy Your champion should not be only the geriatrics department head. Create a coalition: Clinical champion Geriatrician Operational champion Care-management leader Economic champion Population-health executive Technical champion CMIO/informatics/IT Executive sponsor CMO/VP population health That dramatically improves the probability of conversion. --- 9. PATIENT AND CAREGIVER ACQUISITION Don't spend heavily on Facebook ads. Your acquisition engine should initially be: Health system referral → patient enrollment → caregiver invitation → engagement This gives you lower CAC and greater clinical credibility. Later: Employer channel Potentially useful for: employees caring for elderly parents caregiver benefits family-caregiver programs Medicare Advantage Potentially extremely attractive because of medication-adherence quality economics. CMS continues to use medication adherence measures within Part D Star Ratings. Pharmacy Potential channel for: refill synchronization adherence interventions medication reconciliation --- 10. BUSINESS MODEL I recommend: Pilot Free or heavily subsidized. Objective: clinical evidence not revenue. Early commercial $10–$20 PMPM as an initial pricing hypothesis. Include: patient platform caregiver interface clinician dashboard analytics support implementation Enterprise Annual minimum contract. For example: $100k–$250k annual contract depending on population size, integrations and service level. Again, these are pricing experiments, not claims about prevailing market rates. --- 11. FUNDING ROADMAP Stage 1 — Now Raise enough to achieve: regulatory clarity + formal pilot + security readiness Likely financing: founder capital angel investors healthcare angels pre-seed grants Do not raise a huge institutional round solely on an 8-patient prototype. --- 12. NON-DILUTIVE FUNDING This is an unusually strong fit for NIH/NIA. NIA explicitly funds small businesses developing technologies that improve the health and wellbeing of older adults, including digital-health technologies. NIA says its small-business programs provide substantial non-dilutive funding and currently lists awards up to $4.2 million across relevant programs. The timing is particularly relevant: NIH's SBIR/STTR programs were reauthorized in 2026, and new opportunities are currently available. Highest priority NIA SBIR/STTR Especially if your application emphasizes: aging medication management aging in place clinical validation AI-assisted intervention measurable health outcomes NIA also explicitly showcases digital-health and sensing companies it has supported. STTR is particularly interesting Because you already have a strong academic/clinical partnership possibility. STTR requires formal collaboration with a research institution, making it potentially attractive if the geriatrics department is university-affiliated. NSF NSF America's Seed Fund is another possibility for the underlying AI/technical innovation; it advertises up to $2 million in non-dilutive funding and supports AI and medical technologies. However, I would prioritize NIA over NSF because your strongest story is aging + clinical outcomes rather than pure technical novelty. --- 13. INVESTOR NARRATIVE Your pitch should NOT be: > “We built an AI medication reminder for seniors.” That's weak. Instead: Problem Medication nonadherence is a hidden failure point in care for older adults with polypharmacy. Insight Most systems discover nonadherence after a clinical problem appears. Solution A conversational AI layer continuously detects adherence barriers and routes high-risk issues to the care team. Clinical advantage It converts passive medication reminders into early-warning care management. Commercial advantage The buyer already spends money on: care management avoidable utilization chronic disease management medication adherence Moat Over time: patient interaction data adherence-event dataset clinical escalation algorithms workflow integration outcome evidence health-system relationships That's much more defensible than the chatbot itself. --- 14. YOUR 18-MONTH ROADMAP Months 0–3 — Regulatory + study preparation Priority: very high Hire healthcare regulatory consultant Conduct formal FDA software-function assessment Define intended use Freeze initial clinical claims HIPAA risk assessment Security architecture Threat model IRB protocol Statistical analysis plan Study endpoints Patient consent caregiver consent/permissions clinical escalation protocol establish data dictionary establish AI safety monitoring begin FDA Pre-Sub preparation Deliverable Pilot-ready regulated development environment. --- Months 3–6 — FDA + pilot launch Submit/engage FDA through appropriate Q-Sub pathway if device status warrants IRB approval Recruit first 10–15 patients Monitor every interaction Conduct weekly safety review Fix conversational failures measure clinician alert burden refine onboarding Critical rule Don't optimize for AI sophistication. Optimize for: safe + reliable + useful. --- Months 6–12 — Complete 50-patient pilot Target: 50 patients Measure: retention daily engagement adherence detection performance false alerts missed alerts clinician workload patient satisfaction caregiver satisfaction adverse events exploratory utilization Begin commercial conversations with: 5–10 health systems while the pilot is still underway. --- Months 12–15 — Evidence + commercialization Produce: clinical manuscript conference abstract pilot report health-economic model FDA regulatory memo/feedback package enterprise sales deck security package implementation guide ROI calculator Convert: pilot institution → first paid customer --- Months 15–18 — Three contracts Target: Contract #1 Pilot-site expansion. Contract #2 New health system. Contract #3 Value-based-care/MA/ACO-oriented organization. At the same time, launch a larger controlled study. --- 15. KEY KPIs Your board dashboard should contain only a few numbers. Clinical Adherence detection sensitivity False-positive rate Time-to-detection Adherence improvement Engagement Daily completion rate 30/90-day retention Workflow Alerts/patient/month Clinician minutes/patient/month Actionable-alert percentage Commercial Pilot-to-contract conversion Sales cycle ACV CAC Gross margin Clinical economics ED visits hospitalizations medication-related events estimated avoided cost --- 16. THE FIVE BIGGEST RISKS Risk #1 — FDA classification Mitigation: constrain intended use and obtain formal regulatory advice early. Risk #2 — AI hallucination / unsafe advice Mitigation: don't let generative AI independently provide medication decisions. Use constrained workflows, structured medication data and deterministic escalation rules. Risk #3 — Clinician alert fatigue Mitigation: optimize for actionable alerts per clinician, not number of detected problems. Risk #4 — Elderly-user disengagement Mitigation: voice-first, extremely simple interaction, caregiver support and usability testing before the 50-patient study. Risk #5 — Health-system sales cycles Mitigation: start procurement/security discussions during the pilot. --- 17. WHAT I WOULD DO IN THE NEXT 30 DAYS If I were advising this company directly, this would be the priority sequence: Week 1 Freeze the intended use. Write one page answering: > What exactly does the software do, for whom, and what clinical decisions does it not make? This becomes the foundation of the FDA analysis. Week 1–2 Hire: FDA/digital-health regulatory consultant and healthcare privacy/security consultant You don't need either person full-time. Week 2 Turn the geriatrics department head into the formal clinical sponsor/PI. Week 2–3 Build the formal 50-patient protocol. Week 3 Create your statistical analysis plan before collecting data. Week 3–4 Run a structured risk assessment of every possible AI response. Week 4 Start FDA Q-Sub preparation. Simultaneously Begin conversations with 5 prospective health-system customers. --- 18. THE STRATEGIC POSITIONING I WOULD USE Your company should ultimately own this category: > AI-assisted medication safety for high-risk older adults. Not: > AI medication reminder. And not: > AI healthcare chatbot. The product's conceptual workflow should be: Daily patient conversation ↓ Adherence + symptom + access signal ↓ Risk stratification ↓ Clinically constrained escalation ↓ Care-team intervention ↓ Medication adherence improvement ↓ Potential reduction in avoidable utilization That is a real healthcare workflow rather than another consumer app. Bottom line I would rate the concept promising but not yet commercially validated. The strongest assets are already in place: real patients have interacted with the prototype a geriatrics department head is willing to sponsor formal research you have clinical expertise you have technical expertise the problem has a measurable clinical endpoint the payer/health-system environment gives medication adherence economic relevance The biggest gap is regulatory, clinical-study, and health-system commercialization expertise. Your optimal strategy is therefore: Regulatory clarity → rigorous 50-patient pilot → publication → second-site validation → first paid health-system contract → larger controlled study → payer/MA expansion. And I would make one important adjustment to your stated goal: don't promise that the 50-patient study will prove reduced ED visits. Make it a feasibility/safety/detection study designed to generate the evidence and effect-size estimates needed for the larger trial. That will make your FDA discussions, publication, investor story, and eventual health-system sales pitch substantially more credible.